Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032208 | 0.92 | CHRNA7 (0.42) | CHRNA7HTR3AL3MBTL3L3MBTL1ACACB | |
| SCHEMBL4027413 | 0.70 | CHRNA7 (0.50) | CHRNA7HTR3AL3MBTL3L3MBTL1KDM4E | |
| SCHEMBL14381382 | 0.68 | CHRNA7 (0.43) | CHRNA7HTR3AKMT2ACHRNA3 | |
| SCHEMBL5634876 | 0.68 | CHRNA7 (0.43) | CHRNA7HTR3AKMT2ACHRNA3 | |
| SCHEMBL372771 | 0.67 | CHRNA7 (0.43) | CHRNA7HTR3AL3MBTL3L3MBTL1KMT2A | |
| SCHEMBL5635879 | 0.64 | GPR52 (0.39) | CHRNA7KMT2A | |
| SCHEMBL4030570 | 0.63 | CHRNA7 (0.60) | CHRNA7HTR3AL3MBTL3L3MBTL1CHRNA3 | |
| SCHEMBL5416390 | 0.63 | FAAH (0.47) | CHRNA7HTR3AL3MBTL3L3MBTL1 | |
| Benzoic Acid SCHEMBL19834629 | 0.62 | CHRNA7 (0.57) | CHRNA7CYP2D6BCHEACHE | |
| Benzoic Acid SCHEMBL19834628 | 0.62 | CHRNA7 (0.57) | CHRNA7CYP2D6BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244097-A1 | Nicotinic AcetylcholineReceptor Ligands | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | claimed |
| US-20070244097-A1 | Nicotinic AcetylcholineReceptor Ligands | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244097-A1 | Nicotinic AcetylcholineReceptor Ligands | CHRNG, CHRNE, CHRNA1 | CHRNA7 8/4885HTR3A 229/4885CYP2D6 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.